Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices 13169

(4) Affected public who will be asked

or required to respond, as well as a brief

abstract. Primary: Individual or

households. Other: None. This data

collection is the only vehicle for the

Department of Justice (DOJ) to hire

graduating law students. This

application form is submitted

voluntarily, submitted only once a year

by students/judicial law clerks who will

be in this applicant pool only once; and

the information sought only relates to

the hiring criteria established as an

internal matter by DOJ personnel.

(5) An estimate of the total number of

respondents and the amount of time

estimate for an average respondent to

respond: 5,700 respondents at 1 hour

per response.

(6) An estimated of the total public

burden (in hours) associated with the

collection: 5,700 annual burden hours.

Public comment on this proposed

information collection is strongly

encouraged.

Dated: March 14, 1997.

Robert B. Briggs,

Department Clearance Officer, United States

Department of Justice.

[FR Doc. 97–6875 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–24–M

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that by application dated

August 8, 1996, and relevant written

statements of fact received January 8,

1997, B.I. Chemical, Inc., 2820 N.

Normandy Drive, Petersburg, Virginia

23805, made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basis classes of controlled

substances listed below:

Drug Schedule

Methadone (9250) ...................... II

Methadone-intermediate (9254) II

Levo-alphacetylmethadol (LAAM)

(9648).

II

The firm plans to manufacturer the

listed controlled substances in bulk for

distribution to its parent company for

formulation into finished

pharmaceuticals.

Any other such applicant and any

person who is presently registered with

DEA to manufacturer such substances

may file comments or objectives to the

issuance of the above application.

Any such comments or objections

may be addressed, in qunituplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 19,

1997.

Dated: February 21, 1997.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6920 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1311.42 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on May 6, 1996, Glaxo

Wellcome Inc., Attn: Jeffrey A. Weiss,

1011 North Arendell Avenue, P.O. Box

1217, Zebulon, North Carolina 27597–

2309, made application to the Drug

Enforcement Administration to be

registered as an importer of remifentanil

(9739), which did not become a basic

class of controlled substance in

Schedule II until November of 1996.

Therefore, this application was not

processed until remifentanil was

controlled and relevant statements of

fact dated February 12, 1997, were

received.

The remifentanil is being imported for

the production of Ultiva dosage forms

and for research and new product

development.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.54 in

such form as prescribed in 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Acting Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than April 18, 1997.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1311.42 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Acting Deputy

Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42 (a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: March 12, 1997.

Terrance W. Woodworth,

Acting Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6921 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated October 28, 1996, and

published in the Federal Register on

November 27, 1996 (61 FR 60305),

Hoffmann-LaRoche, Inc., 340 Kingsland

Street, Nutley, New Jersey 07110, made

application by renewal to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

levorphanol (9220), a basic class of

controlled substance listed in Schedule

II.

DEA has considered the factors in

Title 21, United States Code, Section

923(a) and determined that the

registration of Hoffmann-LaRoche, Inc.

to manufacture levorphanol is

consistent with the public interest at

this time. Therefore, pursuant to 21

U.S.C. 823 and 28 C.F.R. 0.100 and

0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic class of controlled substance

listed above is granted.
13170 Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices

Dated: February 26, 1997.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6919 Filed 3–19–97; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on November 22,

1996, Knoll Pharmaceuticals, 30 North

Jefferson Road, Whippany, New Jersey

07981, made application by renewal,

which was received for processing

February 4, 1997, to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

hydromorphone (9150), a basic class of

controlled substance in Schedule II.

The firm plans to produce

hydromorphone bulk product and

finished dosage units of dilaudid for

distribution to its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the above application.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 19,

1997.

Dated February 26, 1997.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6917 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on January 27, 1997,

Mallinckrodt Chemical, Inc.,

Mallinckrodt & Second Streets, St.

Louis, Missouri 63147, made

application by renewal to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

Tetrahydrocannabinols (7370) .... I

Drug Schedule

Methylphenidate (1724) .............. II

Cocaine (9041) ........................... II

Codeine (9050) ........................... II

Diprenorphine (9058) .................. II

Etorphine Hydrochloride (9059) .. II

Dihydrocodeine (9210) ............... II

Oxycodone (9143) ...................... II

Hydromorphone (9150) ............... II

Diphenoxylate (9170) .................. II

Hydrocodone (9193) ................... II

Levorphanol (9220) ..................... II

Meperidine (9230) ....................... II

Methadone (9250) ...................... II

Methadone-intermediate (9254) II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ......................... II

thebaine (9333) ........................... II

Opium extracts (9610) ................ II

Opium fluid extract (9620) .......... II

Opium tincture (9630) ................. II

Opium powdered (9639) ............. II

Opium granulated (9640) ............ II

Levo-alphacetylmethadol (9648) II

Oxymorphone (9652) .................. II

Noroxymorphone (9668) ............. II

Alfentanil (9737) .......................... II

Sufentanil (9740) ........................ II

Fentanyl (9801) ........................... II

The firm plans to manufacture the

controlled substances for distribution as

bulk products to its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the above application.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 19,

1997.

Dated: February 26, 1997.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–6918 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Office of Justice Programs

Bureau of Justice Statistics

Agency Information Collection

Activities: Extension of a Currently

Approved Collection; Comments

Requested

ACTION: Notice of information collection

under review; National corrections

reporting program.

The Department of Justice, Office of

Justice Programs, Bureau of Justice

Statistics, has sent the following

information collection to the Office of

Management and Budget (OMB) for

review and clearance in accordance

with the review procedures of the

Paperwork Reduction Act of 1996. The

proposed information collection (60 day

notice) was published in the Federal

Register on January 13, 1997, to obtain

comments from the public and affected

agencies.

The purpose of this notice is to

publish the collection for an additional

30 days until April 18, 1997. Comments

should be directed to OMB, Office of

Information and Regulatory Affairs,

Attention: Department of Justice Desk

Officer, Washington, DC 20503.

Request written comments and

suggestions from the public and affected

agencies concerning the proposed

collection of information. Your

comments should address one or more

of the following four points:

(1) Evaluate whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency, including

whether the information will have

practical utility;

(2) Evaluate the accuracy of the

agencies estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used;

(3) Enhance the quality, utility, and

clarity of the information to be

collected; and

(4) Minimize the burden of the

collection of information on those who

are to respond, including through the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology,

e.g., permitting electronic submission of

responses.

Overview of this information

collection:

(1) Type of Information Collection:

Extension of a currently approved

collection.

(2) Title of the Form/Collection:

National Corrections Reporting Program.

(3) Agency form number, if any,and

the applicable component of the

Department of Justice sponsoring the

collection: Form: NCRP–1A Prison

Admissions Report; NCRP–1B Prison

Release Report; NCRP–1C Parol Exit

Report. Bureau of Justice Statistics,

Office of Justice Programs, United States

Department of Justice.

(4) Affected public who will be asked

or required to respond, as well as a brief

abstract: Primary: State juvenile

corrections agencies. Other: None. This